Somewhat Positive Press Coverage Somewhat Unlikely to Impact Catabasis Pharmaceuticals (CATB) Stock Price

News coverage about Catabasis Pharmaceuticals (NASDAQ:CATB) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catabasis Pharmaceuticals earned a news impact score of 0.16 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 47.9041124209979 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Shares of NASDAQ:CATB traded down $0.01 during midday trading on Monday, reaching $1.76. 114,632 shares of the company’s stock traded hands, compared to its average volume of 930,031. The company has a market cap of $51.39, a P/E ratio of -1.40 and a beta of 0.68. Catabasis Pharmaceuticals has a one year low of $1.09 and a one year high of $3.78.

How to Become a New Pot Stock Millionaire

Catabasis Pharmaceuticals (NASDAQ:CATB) last posted its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.07. The firm had revenue of $0.25 million for the quarter, compared to analysts’ expectations of $0.25 million. sell-side analysts expect that Catabasis Pharmaceuticals will post -0.92 EPS for the current year.

A number of brokerages have recently issued reports on CATB. Zacks Investment Research raised Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Tuesday, March 20th. Wedbush upped their price target on Catabasis Pharmaceuticals from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Tuesday, March 20th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Catabasis Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $5.18.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Catabasis Pharmaceuticals (CATB) Stock Price” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/09/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-catabasis-pharmaceuticals-catb-stock-price.html.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Insider Buying and Selling by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply